Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Next Previous
Trial Profile

Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms P1007; PROFILE 1007; PROFILE-1007
  • Sponsors Pfizer

Most Recent Events

  • 26 Feb 2019 Results of pooled analysis (data cutoff date 15 July 2014) of four clinical trials (NCT00585195,NCT00932451,NCT00932893 and NCT01154140) evaluating renal effects of crizotinib in patients with advanced Non-Small Cell Lung Cancer published in the Journal of Thoracic Oncology
  • 13 Jul 2018 Results assessing Crizotinib efficacy in three prospective studies ((PROFILE 1005, PROFILE 1007, and PROFILE 1014), were published in the Annals of Oncology.
  • 18 Oct 2017 Results of analysis assessing the effect of dexamethasone on steady-state crizotinib exposure using patient data from PROFILE-1001, PROFILE-1005, PROFILE-1007, PROFILE-1014 trials presented at the 18th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top